Pieris Pharmaceuticals, Inc.
Climate Impact & Sustainability Data (2022)
Reporting Period: 2022
Environmental Metrics
Social Achievements
- Approximately 60% of our global workforce was female and 40% of our employees in managerial or supervisory roles were female.
Climate Goals & Targets
Short-term Goals:
- Report topline results from PRS-220 Phase 1 study in the second half of 2023
- Report topline data from Part 2 of elarekibep Phase 2a study by mid-2024
Environmental Challenges
- Global operations subject to various risks (currency fluctuations, tax laws, legal complexities, political instability, compliance with foreign laws, etc.)
- COVID-19 pandemic impacting clinical trials, supply chain, and remote work
- Intense competition from other biotechnology and pharmaceutical companies
- Potential product liability lawsuits
- Dependence on third parties for clinical trials, manufacturing, and supply chain
- Limited operating history and experience
- Uncertainty in regulatory approvals and market acceptance
- Risks associated with scaling up manufacturing to commercial scale
- Potential for biosimilar competition
- Lack of internal marketing and sales force
Mitigation Strategies
- Contract with third parties for disposal of hazardous materials and wastes
- Workers' compensation insurance in Germany
- Multifaceted communication, infrastructure, and behavior modification efforts to address COVID-19
- Collaborations with major pharmaceutical companies
- Product liability insurance
- Careful management of relationships with third parties
- Plans to establish or continue relationships for the supply of drug candidates
- Plans to build marketing, sales, distribution, managerial, and other non-technical capabilities or make arrangements with third parties